Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nuo Therapeutics's Business Segments
Nuo Therapeutics's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- Single Reportable Segment100%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 1 | 100% |
Revenue by Product & Service Category - Q2 FY2025
- Product89.3%
- License10.7%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1 | 89.3% |
| License | $ 0 | 10.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue by Product & Service Category -
- License7%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | 7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Nuo Therapeutics
Nuo Therapeutics, Inc. was a biopharmaceutical company specializing in the development and commercialization of innovative products for the treatment of chronic wounds. The company was headquartered in Gaithersburg, Maryland, United States.
Nuo Therapeutics was primarily focused on developing therapeutic solutions that utilize the body's own regenerative capabilities to treat chronic wounds, such as diabetic foot ulcers and venous leg ulcers. The company aimed to address the unmet medical needs of patients suffering from these conditions, which can result in severe complications if left untreated.
One of the key products developed by Nuo Therapeutics was Aurix, a biodynamic hematogel. Aurix was a platelet and plasma-based therapy derived from the patient's own blood, containing a high concentration of platelets and other regenerative factors. It had the potential to accelerate wound healing by stimulating tissue repair and promoting angiogenesis, the formation of new blood vessels.
The innovative nature of Aurix led to its FDA approval and subsequent commercialization, making it the flagship product for Nuo Therapeutics. The company worked closely with healthcare providers to incorporate Aurix into their wound care protocols, aiming to improve patient outcomes and reduce healthcare costs associated with chronic wound treatment.
Nuo Therapeutics also focused on research and development of advanced wound care therapies, exploring new treatment modalities beyond Aurix. The company aimed to leverage its expertise in regenerative medicine and wound healing to develop novel products that could revolutionize the standard of care in the field.
In addition to its product development efforts, Nuo Therapeutics had a strong focus on clinical trials and gathering scientific evidence to support the efficacy of its products. The company conducted numerous studies to evaluate the safety and effectiveness of Aurix in various patient populations, enhancing the clinical understanding of its benefits.
Despite its promising approach to wound care, Nuo Therapeutics faced significant challenges in its financial stability. In 2018, the company filed for bankruptcy and subsequently liquidated its assets. As a result, its operations came to a halt, and Nuo Therapeutics ceased to exist as an independent entity.
Overall, Nuo Therapeutics, Inc. was a biopharmaceutical company dedicated to developing and commercializing innovative solutions for chronic wound treatment. Its focus on regenerative medicine and advanced wound care techniques aimed to improve the lives of patients suffering from chronic wounds.
Nuo Therapeutics was primarily focused on developing therapeutic solutions that utilize the body's own regenerative capabilities to treat chronic wounds, such as diabetic foot ulcers and venous leg ulcers. The company aimed to address the unmet medical needs of patients suffering from these conditions, which can result in severe complications if left untreated.
One of the key products developed by Nuo Therapeutics was Aurix, a biodynamic hematogel. Aurix was a platelet and plasma-based therapy derived from the patient's own blood, containing a high concentration of platelets and other regenerative factors. It had the potential to accelerate wound healing by stimulating tissue repair and promoting angiogenesis, the formation of new blood vessels.
The innovative nature of Aurix led to its FDA approval and subsequent commercialization, making it the flagship product for Nuo Therapeutics. The company worked closely with healthcare providers to incorporate Aurix into their wound care protocols, aiming to improve patient outcomes and reduce healthcare costs associated with chronic wound treatment.
Nuo Therapeutics also focused on research and development of advanced wound care therapies, exploring new treatment modalities beyond Aurix. The company aimed to leverage its expertise in regenerative medicine and wound healing to develop novel products that could revolutionize the standard of care in the field.
In addition to its product development efforts, Nuo Therapeutics had a strong focus on clinical trials and gathering scientific evidence to support the efficacy of its products. The company conducted numerous studies to evaluate the safety and effectiveness of Aurix in various patient populations, enhancing the clinical understanding of its benefits.
Despite its promising approach to wound care, Nuo Therapeutics faced significant challenges in its financial stability. In 2018, the company filed for bankruptcy and subsequently liquidated its assets. As a result, its operations came to a halt, and Nuo Therapeutics ceased to exist as an independent entity.
Overall, Nuo Therapeutics, Inc. was a biopharmaceutical company dedicated to developing and commercializing innovative solutions for chronic wound treatment. Its focus on regenerative medicine and advanced wound care techniques aimed to improve the lives of patients suffering from chronic wounds.
Nuo Therapeutics, Inc. is a biotechnology company primarily focused on developing and commercializing innovative treatments for patients with chronic wounds. The companys portfolio is centered around its proprietary Aurix system and related therapeutic products aimed at enhancing the healing process for various types of wounds.
Segments
1. Wound Care: Nuo Therapeutics predominantly operates in the wound care segment, targeting chronic wounds which are a significant burden for healthcare systems. Chronic wounds can arise from various conditions, including diabetes and venous insufficiency, and are characterized by their prolonged healing times.
2. Regenerative Medicine: This segment focuses on therapies that promote healing and tissue regeneration. Nuo Therapeutics emphasizes the development of products that leverage the bodys natural healing processes, aiming to restore normal function and structure to damaged tissues.
Products
1. Aurix® System:
- Description: Aurix is a cell-based therapy platform designed to treat chronic and non-healing wounds. The system processes a patient’s own blood to create a concentrated source of platelets, growth factors, and other bioactive components that are essential for the healing process.
- Clinical Use: Primarily used for treating diabetic ulcers, pressure ulcers, and venous ulcers, the Aurix system promotes angiogenesis, collagen deposition, and the overall healing cascade. It enhances local cellular activity and supports tissue regeneration.
2. NuoGuard®:
- Description: This product line includes topical applications and dressings that provide a protective environment conducive to healing. Utilizing advanced materials, these dressings may incorporate antimicrobial agents and are designed to maintain optimal moisture levels.
- Clinical Use: NuoGuard products are effective in managing a variety of wounds, including surgical wounds, traumatic wounds, and burns. They aim to prevent infection and promote quicker healing times.
3. Autologous Platelet Rich Fibrin (PRF):
- Description: Another component within the Nuo product range, this therapy utilizes the patients own blood to produce a fibrin matrix that contains a high concentration of growth factors.
- Clinical Use: It is used to enhance healing in surgical procedures and traumatic wounds, accelerating tissue repair and regeneration through the natural properties of the components derived from the patients blood.
Services
1. Clinical Education and Training: Nuo Therapeutics offers training programs for healthcare professionals to educate them about the benefits and application techniques of their products. This includes hands-on workshops, webinars, and comprehensive clinical support for optimal product utilization.
2. Data Collection and Reporting: The company may provide services around data collection related to treatment outcomes using their products, facilitating evidence-based practices among healthcare providers.
3. Consultative Services: Nuo Therapeutics supports healthcare facilities in establishing best practices for wound management, utilizing their products to optimize patient outcomes. This consultative approach includes assessments of patient populations and the development of tailored treatment protocols.
Market Position and Impact
Nuo Therapeutics, Inc. strives to position itself as a leader in the wound care and regenerative medicine markets by focusing on patient-centric solutions that leverage innovative technologies. The companys commitment to research and development aims to address unmet needs in chronic wound management while improving the quality of care for patients experiencing slow-healing wounds.
In summary, Nuo Therapeutics, Inc. offers a specialized range of products and services designed to enhance the healing of chronic wounds. With a strong focus on innovative, cell-based therapies and comprehensive clinical support, the company works to improve patient outcomes and advance wound care practices in healthcare settings.
Segments
1. Wound Care: Nuo Therapeutics predominantly operates in the wound care segment, targeting chronic wounds which are a significant burden for healthcare systems. Chronic wounds can arise from various conditions, including diabetes and venous insufficiency, and are characterized by their prolonged healing times.
2. Regenerative Medicine: This segment focuses on therapies that promote healing and tissue regeneration. Nuo Therapeutics emphasizes the development of products that leverage the bodys natural healing processes, aiming to restore normal function and structure to damaged tissues.
Products
1. Aurix® System:
- Description: Aurix is a cell-based therapy platform designed to treat chronic and non-healing wounds. The system processes a patient’s own blood to create a concentrated source of platelets, growth factors, and other bioactive components that are essential for the healing process.
- Clinical Use: Primarily used for treating diabetic ulcers, pressure ulcers, and venous ulcers, the Aurix system promotes angiogenesis, collagen deposition, and the overall healing cascade. It enhances local cellular activity and supports tissue regeneration.
2. NuoGuard®:
- Description: This product line includes topical applications and dressings that provide a protective environment conducive to healing. Utilizing advanced materials, these dressings may incorporate antimicrobial agents and are designed to maintain optimal moisture levels.
- Clinical Use: NuoGuard products are effective in managing a variety of wounds, including surgical wounds, traumatic wounds, and burns. They aim to prevent infection and promote quicker healing times.
3. Autologous Platelet Rich Fibrin (PRF):
- Description: Another component within the Nuo product range, this therapy utilizes the patients own blood to produce a fibrin matrix that contains a high concentration of growth factors.
- Clinical Use: It is used to enhance healing in surgical procedures and traumatic wounds, accelerating tissue repair and regeneration through the natural properties of the components derived from the patients blood.
Services
1. Clinical Education and Training: Nuo Therapeutics offers training programs for healthcare professionals to educate them about the benefits and application techniques of their products. This includes hands-on workshops, webinars, and comprehensive clinical support for optimal product utilization.
2. Data Collection and Reporting: The company may provide services around data collection related to treatment outcomes using their products, facilitating evidence-based practices among healthcare providers.
3. Consultative Services: Nuo Therapeutics supports healthcare facilities in establishing best practices for wound management, utilizing their products to optimize patient outcomes. This consultative approach includes assessments of patient populations and the development of tailored treatment protocols.
Market Position and Impact
Nuo Therapeutics, Inc. strives to position itself as a leader in the wound care and regenerative medicine markets by focusing on patient-centric solutions that leverage innovative technologies. The companys commitment to research and development aims to address unmet needs in chronic wound management while improving the quality of care for patients experiencing slow-healing wounds.
In summary, Nuo Therapeutics, Inc. offers a specialized range of products and services designed to enhance the healing of chronic wounds. With a strong focus on innovative, cell-based therapies and comprehensive clinical support, the company works to improve patient outcomes and advance wound care practices in healthcare settings.